News Image

Century Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates

Provided By GlobeNewswire

Last update: Aug 8, 2024

– Initiation of Phase 1 CALiPSO-1 Trial of CNTY-101 in Systemic Lupus Erythematosus, marking strategic expansion into autoimmune disease; protocol amended to include additional cohort of Lupus Nephritis patients –

Read more at globenewswire.com

CENTURY THERAPEUTICS INC

NASDAQ:IPSC (6/23/2025, 8:25:44 PM)

After market: 0.5749 0 (-0.02%)

0.575

-0.01 (-1.19%)



Find more stocks in the Stock Screener

Follow ChartMill for more